Published Technical Disclosure Archive

Next-Generation Spinal Muscular Atrophy Treatment System

Publication ID: 24-11857599_0005_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Spinal Muscular Atrophy Treatment System,” Published Technical Disclosure No. 24-11857599_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857599_0005_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,599.

Summary of the Inventive Concept

A comprehensive system for treating spinal muscular atrophy, combining gene editing, ALK4:ActRIIB heteromultimer modulation, and stem cell therapy to enhance motor neuron survival and prevent disease progression.

Background and Problem Solved

The original patent's method of treating spinal muscular atrophy using ALK4:ActRIIB heteromultimer has limitations, including the need for repeated administrations and potential side effects. The new inventive concept addresses these limitations by integrating gene editing and stem cell therapy to provide a more comprehensive and sustainable treatment approach.

Detailed Description of the Inventive Concept

The system consists of three modules: a gene editing module using CRISPR-Cas9 to increase SMN protein levels, an ALK4:ActRIIB heteromultimer module to modulate TGF-beta superfamily signaling, and a stem cell therapy module to replace damaged motor neurons. The system can be configured to detect SMN protein levels and predict disease progression, allowing for personalized treatment and monitoring. The ALK4:ActRIIB heteromultimer module can be administered in combination with small molecule inhibitors of the TGF-beta superfamily to enhance its effect.

Novelty and Inventive Step

The new claims introduce a paradigm shift in spinal muscular atrophy treatment by combining gene editing, ALK4:ActRIIB heteromultimer modulation, and stem cell therapy in a single system. The integration of these components provides a more comprehensive and sustainable treatment approach, overcoming the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the system could include using different gene editing tools, such as zinc finger nucleases or adenine base editors, or incorporating additional therapeutic modules, such as RNA interference or antisense oligonucleotides. The system could also be adapted for use in other neurological disorders characterized by motor neuron degeneration.

Potential Commercial Applications and Market

The next-generation spinal muscular atrophy treatment system has significant commercial potential in the pharmaceutical and biotechnology industries, with a target market of patients with spinal muscular atrophy and their families. The system's comprehensive approach and potential for personalized treatment could provide a competitive advantage in the market.

CPC Classifications

SectionClassGroup
A A61 A61K38/1841
A A61 A61K31/7125
A A61 A61K38/18
A A61 A61K45/06
A A61 A61P21/00
C C07 C07K14/71
C C12 C12N15/113
A A61 A61K38/179
C C07 C07K2319/30
C C07 C07K2319/32
C C12 C12N2310/11
C C12 C12N2320/31

Field of Art

Biotechnology and medical therapeutics, specifically neuromuscular disorder treatment, focusing on genetic and protein-based interventions for spinal muscular atrophy (SMA)

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in molecular biology, genetics, or biomedical engineering, possessing expertise in gene editing, protein engineering, and therapeutic development for neurological disorders

Obviousness Rationale

A person having ordinary skill in the art would recognize that combining gene editing, protein modulation, and stem cell approaches represents a predictable and logical extension of the source patent's ALK4:ActRIIB heteromultimer treatment strategy. The PTD's proposed system integrates known therapeutic techniques with the existing molecular mechanism disclosed in the original patent. Such combinatorial approaches are standard practice in developing comprehensive treatment strategies for complex genetic disorders.

Obvious Combinations & Variations

Source Patent Element
ALK4:ActRIIB heteromultimer for treating spinal muscular atrophy
PTD Variation
Adding CRISPR-Cas9 gene editing to modify SMN1 gene expression
Obviousness Reasoning
Gene editing is a well-established technique for addressing genetic deficiencies, and a PHOSITA would recognize its potential to complement protein-based therapies in a predictable manner
Source Patent Element
Method of treating SMA by modulating protein levels
PTD Variation
Incorporating stem cell therapy to replace damaged motor neurons
Obviousness Reasoning
Stem cell replacement is a known regenerative medicine approach for neurodegenerative conditions, representing a finite and obvious solution for enhancing treatment effectiveness
Source Patent Element
Treatment targeting motor neuron survival
PTD Variation
Adding small molecule TGF-beta superfamily inhibitors to enhance therapeutic efficacy
Obviousness Reasoning
Combination therapies are a standard approach in medical treatment, and a PHOSITA would find it obvious to explore synergistic molecular interventions
Source Patent Element
SMA treatment method focusing on protein modulation
PTD Variation
Implementing a monitoring system to track SMN protein levels and predict disease progression
Obviousness Reasoning
Personalized medicine approaches involving real-time biomarker monitoring are a predictable technological advancement in precision therapeutic strategies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857599 and the comprehensive technical disclosure herein, a person having ordinary skill in the art would find the proposed treatment system and methods obvious and anticipated, particularly given the predictable combination of known genetic, protein-based, and cellular therapeutic techniques for addressing spinal muscular atrophy. The disclosed variations represent routine optimization and combination of existing molecular intervention strategies within the field of neuromuscular disorder treatment.

Original Patent Information

Patent NumberUS 11,857,599
TitleCompositions and methods for treating spinal muscular atrophy
Assignee(s)ACCELERON PHARMA INC.